As evident in Table 1, there are compounds which can also sensitize CML LSCs to TKIs and eliminate them by disrupting the PI3K/AKT/mTOR pathway. The gene discussed is AKT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.